AFMD - Affimed and Roche collaborate to study AFM24 in solid tumors

Affimed N.V. (AFMD) has surged ~10.6% in the premarket after announcing that it has entered a research collaboration with Roche (RHHBY) to study its innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).As per the terms of the agreement, Affimed will fund and advance a Phase 1/2a clinical trial for AFM24 in combination with atezolizumab, and Roche will supply atezolizumab for the clinical trial.The trial will establish the dosing regimen and assess the safety and potential activity in patients with advanced solid epidermal growth factor receptor ("EGFR") expressing malignancies whose disease has progressed after treatment with previous anticancer therapies.In April 2020, dosing got underway in a Phase 1/2a trial evaluating AFM24 as a monotherapy in patients with advanced solid tumors whose cancer has progressed after prior treatment.

For further details see:

Affimed and Roche collaborate to study AFM24 in solid tumors